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Abstract
Vitiligo and melasma are acquired pigmentary disorder of the skin and also the leading cause 
for dermatologist consultation in South Asian countries like Nepal. Vitiligo vulgaris and melasma are 
common examples for depigmentary and hyperpigmentary conditions respectively. There are multiple 
proven medical, surgical and combined modalities of managing them but the challenge in our part of 
the world with majority of Fitzpatrick skin types III-V is; it remains a psychosocial-cosmetic disease. 
is slowly progressive, either by centrifugal expansion of current lesion 
and the appearance of a new lesion. May remain asymptomatic, 
may itch and have a propensity to sunburn. Koebner phenomenon 
develops in areas of friction &/ or trauma. It typically appears in 
exposed areas such as face and hands. Chronic persistent, spontaneous 
repigmentation is uncommon and occurs in a perifollicular pattern. 
In some cases begins insidiously in sun-exposed areas during the 
spring and summer months. Severe sunburn, pregnancy, skin trauma, 
and emotional stress may precede the onset.
According to the area of involvement various types and subtypes 
of vitiligo are NSV (Non segmental vitiligo); focal, mucosal, 
acrofacial, generalised, universal, SV (segmental vitiligo); focal, 
mucosal, unisegmental, bisegmental or plurisegmenntal, mixed 
and unclassified like; focal at onset, multifocal, asymmetrical, non-
segmental, mucosal type (one site) [5].
Diagnosis
Mostly the diagnosis is made clinically. However woods lamp, 
a handled (UV) irradiation device or even skin punch biopsy for 
histopathological confirmation can be done.
Review of current clinical studies of vitiligo 
treatments
Although it is relatively resistant to most of the treatments, 
spontaneous repigmentation occurs in more than 1-25% of cases. 
Some studies stated occurrence of repigmentation in 10-20% of the 
cases.
Results of recent (since year 2009) clinical studies in vitiligo field 
are overviewed, with emphasis on their contribution to improved 
vitiligo management. The review includes all kinds of clinical 
studies, ranging from double-blind randomized controlled trials 
with objective assessment of treatment efficiency and evaluation of 
patient’s satisfaction, to pilot trials aiming to preliminary address a 
question of treatment utility
Introduction
Vitiligo and melasma are acquired pigmentary disorder of the 
skin and also the leading cause for dermatologist consultation in 
South Asian countries like Nepal. Clinically vitiligo is characterised 
by well circumscribed, depigmented macules and patches secondary 
to selective destruction of melanocytes in the skin and mucous 
membrane, whereas melasma is characterized by symmetrical 
hyperpigmented macules on the face. 
Vitiligo
Epidemiology 
Vitiligo vulgaris is a common clinical-type skin and mucosal 
disorder observed in Nepal. It can affect all skin types and affects both 
sexes equally however, female usually acquire the disease earlier than 
males. It can occur at any age, cases have been reported as early as 
6weeks after birth. Half of the patients develop the disease before the 
age of 20 years. Onset at an advanced age occurs although unusual 
and should raise concern about associated diseases like thyroid 
dysfunction, rheumatoid arthritis, diabetes mellitus, alopecia areata, 
atopic dermatitis [1-3].
With a global incidence between 1 to 2%, highest incidence has 
been reported in India and Mexico. It accounted for 2.82% of the total 
outpatients seen in two referral hospitals of Nepal. Thus South-Asian 
countries could be a significant contributor to the global incidence of 
this disorder. 
Etiopathogenesis
Of several pathophysiologic theories the most prominent are 
autoimmune phenomenon associated with underlying genetic 
predisposition, neurohormonal and autocytotoxic theory [4,5].
Presenting features 
Vitiligo presents as well circumscribed, depigmented macules 
and patches with convex borders, surrounded by normal skin which 
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Sun protection: Sunscreen helps prevent sunburn and lessen 
photo damage as well as the chance that Koebner phenomenon will 
occur. Sunscreens also decrease tanning of the uninvolved skin and 
therefore lessen the contrast with vitiliginous lesions. 
Cosmeceuticals: such as camouflage products and self-tanning 
dyes consist of three steps; including application of base cream, cover 
with a foundation selected for each patient then dry up with finishing 
powder. The newer self-tanning creams containing dihydroxyacetone 
are useful for light-skinned and olive complexioned patients with 
acral lesions [6].
Topical corticosteroids: Topical corticosteroids are useful for 
localized vitiligo. Class 1, 2 or 3 topical steroids showed <20% of 
BSA achieving 75% repigmentation (6-8 weeks cycle, alternate with 
tacrolimus) The effectiveness of intra-venous methylprednisolone 
(8mg/kg bodyweight) administered on 3consecutive days in patients 
with generalised vitiligo, showed that high-dose glucocorticosteroid 
pulse therapy may represent a therapeutic option in patients with 
generalised progressive vitiligo, and should be further evaluated in 
a prospective, randomised, clinical trial. In their study, 85%of the 
patients presenting with progressive disease showed cessation of 
disease progression after the infusion therapy. Repigmentation was 
observed in 71% of the patients with progressive vitiligo.
Calcineurin inhibitor: Lepeet al. report concluded that tacrolimus 
is almost as effective as clobetasol and is better for sensitive areas (e.g. 
eyelids) because, unlike clobetasol, it does not cause skin atrophy. 
The mean percentages of repigmentation were Clobetasol 49.3% and 
Tacrolimus 41.3%. In their study, 90% of patients experienced some 
repigmentation after 2months treatment. Tacrolimus was observed 
to be the most effective on head and neck lesions compared to trunk 
and extremities, with shorter disease duration and darker skin photo 
type predicting better response. In addition, response to tacrolimus 
monotherapy appeared to be better in children. In addition van 
Geel et al. studied experimentally induced koebnerization and also 
stressed a necessity of early treatment during inflammatory phase 
accompanying koebnerization. In this study, in line with others 
observation, both tacrolimus and mometasone furoate were equally 
efficient in halting spread of the lesions. Tacrolimus in combination 
with oral prednisolone was efficient in treatment of newly manifested 
vitiligo. Pimecrolimus was less efficient than topical mometasone in 
paediatric vitiligo treatment (mean repigmentation 42% vs. 65%), 
with pimecrolimus being efficient only on head and neck, whereas 
mometasone could be used for treatment of any part of the body [7].
We usually prescribe Tacrolimus at 0.03% preparation alone or 
in combination with mid-potency steroid resulting in repigmentation 
among 60-80% of cases and also help stabilize the progression of the 
lesions.
Vitamin-D derivative: A number of studies have recently reported 
that the treatment with vitamin D compounds or their combination 
with ultraviolet light or corticosteroid enhances repigmentation 
in vitiligo; however, the casual relationship at the cellular and 
molecular levels has not so far been investigated. Calcipotriol plus 
photochemotherapy also appears very promising but certainly 
requires further evaluation. In a pilot study, topical calcipotriene 
and betamethasone dipropionate is a promising combination to 
treat facial vitiligo, but because of lack of control group, the definite 
conclusion is hard to be made [8].
Phototherapy: (UV-A, narrowband UV-B), Photochemotherapy 
(psoralen plus UV-A [PUVA]), Psoralen with sunlight (PUV Asol)
Phototherapy is an acknowledged first-line option in generalised 
vitiligo treatment. Topical and systemic PUVA therapy may require 
100-300 treatment sessions to achieve complete repigmentation 
.NBUVB is as efficient as topical PUVA but with fewer adverse effects 
(given 2-3 X/week with starting dose of 100-250 mJ/cm2, increased in 
increments of 10-20% until mild asymptomatic erythema achieved). 
The major side effects of photochemotherapy are severe phototoxic 
reaction, blistering, hyperpigmentation, photo-allergic reaction, 
hyperkeratosis of lesional skin, skin malignancies.
NBUVB can be used in children, pregnant or lactating women 
and patients with hepatic or kidney dysfunction. The combination 
of PUVA and calcipotriol is highly effective and works faster and 
may be used for shortening the therapy with PUVA in the treatment 
of vitiligo. Oral PUVA using 8-MOP (0.4-0.6mg/kg) administered 
2X/week; initial dose of UVA is usually 0.5-1.0 J/cm2.  Visible light 
(635nm low energy laser) for SV treatment resulted in 7out of 14 
patients responding to the treatment (response was defined as 
achieving at least 25% of repigmentation) thus confirming efficiency 
of visible light in SV treatment.
In our context also NBUVB seems to provide excellent results 
among patients with generalized, progressive type of vitiligo; one of 
the limitations is the frequent hospital visits. 
In stable, localised vitiligo topical 8-methoxy psoralen along with 
appropriate sun exposure are showing good results.
Surgical techniques 
Cosmetic tattooing is used for localised stable vitiligo, especially 
of the mucosal type. Pigments used in cosmetic tattoo are inert 
iron oxides that are available in more than 15shades. The colour 
is implanted into the dermal layer with specialised techniques and 
cannot be washed off. Of the general tendency, younger patients 
respond usually better, with facial and trunk lesions repigmenting 
better than those with acral location. Dermatosurgical procedures 
offer a good alternative and option of management in depigmentary 
disorders. However, it is important to counsel the patients regarding 
the disease, procedures and their expected outcome, and follow strict 
criteria while selecting patients, so that the outcome is satisfactory 
both for the doctor and the patient. The choice of procedure must be 
individualized, considering the size of the lesion to be treated, and 
readily available facilities [3,5,9-11].
Procedures like punch grafting and split thickness skin grafting 
or epidermal grafting are inexpensive, relatively simple to perform 
and thus can be performed as office procedures. These techniques 
can be modified to minimize known adverse effects and achieve 
superior results. Side effects noted were like occasional perigraft halo, 
hypertrophic scar, koebnerization, hypo or hyperpigmentation 2year 
follow up of 49 patients who underwent autologous non-cultured 
epidermal method to treat pediatric vitiligo. 
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At our hospital we have experienced excellent outcome among our 
patients especially with stable localized vitiligo areas not responding 
to topical treatments.
Dermatosurgical procedures produce better results when 
combined with post-operative PUVA and should be advised for all 
patients.
There is scope for improving the technique of split-thickness 
skin grafting to harvest uniformly thin grafts using simple hand held 
dermatome. This technique would ensure an inexpensive, time saving 
procedure with equally well, if not excellent, cosmetic outcome. 
Autologous cultured epidermal grafting (CEA) containing only 
melanocytes or both keratinocytes and melanocytes used either as 
sheets or cell suspensions have proved to be effective in treating stable 
vitiligo but are laboratory dependent. This has eliminated the need of 
TCL and has been adapted to successfully repigment stable vitiligo 
lesions. With the introduction of autologous cell harvesting devices 
(Recell Kit) the methodology is further simplified [3,5,6]
Excimer laser: The most recent effective and approved therapy for 
vitiligo is the 308-nm excimer laser with or without topical calcineurin 
antagonists. Efficiency was revealed for excimer laser treatment in; 
children with 50% of treated lesions achieved 50%repigmentation, 
adults 60.4% of patches repigmented for more than 75%. Besides 
surgical methods EL might be an option for SV patients. For vitiligo 
universalis, treatment with topical 4-methoxyphenol and Q-switched 
(QS) ruby laser has been effective. It destroys the melanosome in 
melanocytes and keratinocytes by selective photothermolysis [12-14].
Combination therapies: In controlled trial tacrolimus vs. 
fluticasone propionate, mometasone furoate and clobetasol 
propionate in children with general conclusion of similar efficiency 
of steroid and tacrolimus. Both agents showed poor results when 
SV lesion was treated. Combination of topical tacrolimus, targeted 
NBUVB and systemic prednisolone showed promising results in 
recently onset UV resistant areas, such as bony prominences of the 
extremities.
In combination with NBUVB, tacrolimus showed better results 
compared to placebo. There were potential benefits gained from 
combination of Monochromatic excimer laser (MEL) and topical 
tacrolimus to enhance clinical response.
Double blind studies show that pimecrolimus 1% cream 
combined with NBUVB is superior to placebo, especially for facial 
lesions. Combining blister roof transplantation (BR) with khellin 
in liposomes and ultraviolet light (KLUV) in the treatment of 
recalcitrant vitiligo patches [12-14].
Complementary therapies: Ginkgo Biloba and leflunomide 
have immune modulating properties. In a pilot study of Szczurko et 
al., potency of oral Ginkgo biloba extract to halt the progression of 
active vitiligo has been evaluated. Previously, statistically significant 
cessation of the disease activity was observed in placebo controlled 
clinical trial. Disease progression was stopped in a 12-week follow 
up after leflunomide therapy. At our OPD Ginkgo Biloba are also 
prescribed and have proven to help stabilize the progression of disease 
to quite an extent. It is a very good alternative to usually prescribed 
oral steroids.
Pseudocatalase creams with Dead Sea climatotherapy are also 
compatible with repigmentation. Analysis of a large cohort study 
of patients revealed that 85% patients responded to the therapy. 
The authors concluded that Dead Sea climatography is an effective 
treatment modality of vitiligo with relatively few side effects, Topical 
melagenina 1 and 2 solution manufactured in Cuba at Cetro de 
Histoterapia, Havana is an alcoholic extract from human placenta, 
containing placental lipoprotein fraction. Its active ingredients are 
melagenina and calcium chloride. It generally works by triggering the 
production of melanocytes [12-14].
Oral L-phenylalanine is a product of Venezuela, VitilVenz, 
containing coenzyme Q10, vitamins C and E and other natural 
stimulators of mitochondria was tested in 100 patients and control 
subjects with positive results. 
Patients with extensive disease (>50% body area) who desire 
permanent matching of the skin colour but for whom repigmentation 
is not possible can be depigmented with 20%monobenzyl ether of 
hydroquinone, 2times daily for 9-12months.
Natural treatments
Vitiligo oil compounds such as psoralea Coryli Folia/ breadroot, 
coconut oil, kala jeera/ nigella/ black cumin, berberis vulgaris/ 
barberry root/ trailing mahonia, St. John Wort are commonly used 
herb for this condition; the herb oil can be applied to the skin [12-14].
Wild Duckweed (Lemna Minor) works by reactivating 
melanocytes.
Bergamot essential oil has substances in it called Bergaptenes 
that have strong photosensitising action may help turn back on 
melanocytes which are activated by ultraviolet light, pepper has 
direct antioxidant activity against various free radicals and scientists 
recently discovered that can even stimulate colouration of the skin in 
an animal model vitiligo.
Melasma
Epidemiology
Melasma predominantly affects Fitzpatrick skin prototype 3-4 
and often lasts for many years after pregnancy. In Southeast Asia, the 
prevalence has been reported to be as high as 40% in females and 20% 
in males. In a study by B Dwari, S Palaian, A Poudel, S Prabhu clinical 
profile and management pattern of melasma patients in Western 
Nepal: A Hospital Based Study concluded the clinical profile and 
treatment pattern of the melasma patients were analyzed. Majority of 
the patients were females and were of child bearing age. Sunscreens 
were the most commonly used medications and the drug therapy was 
associated with huge economic impact.
The prevalence of melasma is unknown. Studies from Mexico 
and Peru found that melasma accounted for 4 to 10% of new 
dermatology hospital referrals. It is more common in women than in 
men and is rare before puberty. Melasma occurs during pregnancy in 
approximately 25% of cases. Among pregnant women, the prevalence 
of melasma ranges between 15 and 50%.
Although no race is spared, melasma is far more common in 
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in melasma lesions. This induces stimulation of melanogenesis and 
increased transfer of melanin from melanocytes to keratinocytes.
iNOS and nuclear factor-kappa B pathways have also been found 
to be implicated in melasma pathogenesis. In a study by Jo et al. iNOS 
expression was found to be increased in melasma lesions [21].
The most affected biological process in melasma is lipid 
metabolism [20]. Lipid metabolism genes, such as peroxisome 
proliferator-activated receptor alpha (PPAR), arachidonate 15- 
lipoxygenase, PPAR gamma coactivator 1 alpha, type B (ALXO 
15B), diacylglycerol o-acyltransferase 2-like 3 were found to be down 
regulated. This down regulation is caused by chronic UV exposure 
[22]. Another change seen in melasma skin is thinning of the stratum 
corneum (SC) as found in skin biopsies that show rete ridge flattening 
and epidermal thinning? SC thinning coupled with disturbed lipid 
synthesis is responsible for the impaired SC integrity and a delayed 
barrier recovery rate seen in melasma skin [24].
In a study by Lee  et al. [23], melanin index, erythema index, 
and SC hydration were found to be significantly higher in lesional 
melasma skin as compared to perilesional normal skin. This proves 
that prominent vascularization accompanies hyperpigmentation 
[24].
Prolonged UV exposure-induced dermal inflammation and 
fibroblast activation may upregulate stem cell factors in the melasma 
dermis, causing increased melanogenesis.
The above findings emphasize the need for devising treatment 
options targeting these pathogenic factors in melasma.
Review of current clinical studies of melasma 
treatments
Sunscreen and camouflage: Sunscreen plays a vital role for 
melasma prevention as well as control and affects the overall outcome 
of any treatment options for patients. Depending upon the skin 
type and sun exposure appropriate SPF (sun protection factor) are 
prescribed and advised to be used on regular basis. Camouflage 
is advised for patients who need temporary coverage of the 
hyperpigmentation. It is best to advice camouflage whenever required 
but always along with sunscreen.
Phenolic compounds: Current role of Hydroquinone (HQ): HQ 
is a dihydric phenol that inhibits the conversion of dopa to melanin 
by inhibiting the tyrosinase enzyme. Other proposed mechanisms 
of action include the inhibition of RNA and deoxyribonucleic acid 
synthesis and destruction of melanocytes.
HQ is considered the gold standard of treatment for melasma. 
It is used at a concentration of 2-4%. Its efficacy is enhanced when 
used in combination with other agents. These combinations 
include the Kligman’s formula (5% HQ, 0.1% tretinoin, and 0.1% 
dexamethasone), modified Kligman’s formula (4% HQ, 0.05% 
tretinoin and 1% hydrocortisone acetate), Pathak’s (2% HQ and 0.05-
0.1% tretinoin) and Westerhof’s formula (4.7% N-acetylcysteine, 
2% HQ and 0.1% triamcinolone acetonide) [25]. Combination of 
microencapsulated HQ 4% with retinol 0.15% and antioxidants has 
also been tried in melasma with studies showing improvement in 
women and in dark skinned individuals. It is a common and growing 
cosmetic concern among Nepalese population with Fitzpatrick skin 
types III-V. 
In a retrospective study conducted by Anil K. Jha [15], Amatya 
Benl, Amatya Amit, Pattern of Skin Diseases in Kathmandu Nepal, 
Nepal Journal of Dermatology, Venereology and Leprology; melasma 
composed the third most common dermatological affection. The total 
population included 3224, new dermatological cases were 235, 7.29% 
cases of melasma were seen over a period of one year; 203 (12.69%) 
were females and 32 (1.93%) were males [16].
Clinical and pathologic features
Melasma presents as symmetrical hyperpigmentation appearing 
as light brown to dark, muddy brown macules and patches on the 
face, especially the forehead, cheeks, nose, upper lip or chin. The 
authors found 2basic forms; Epidermal form lesions which enhance 
when viewed under wood lamp, featuring melanin deposition mainly 
in the basal and suprabasal layers  and dermal form with superficial 
and deep perivascular melanophages in the dermis which do not 
enhance implying an increase in dermal melanin content.
Dermoscopy can be used for the diagnosis of melasma. Lesions 
of melasma show diffuse reticular pigmentation in various shades 
of brown with sparing of follicular openings. Dermal melasma 
shows diffuse dark brown to greyish pseudo reticular pigmentation. 
Annular, honeycomb and arcuate structures may be seen.
Etiopathogenesis
Studies have confirmed that both melanocytosis (increased 
number of melanocytes) as well as increased melanogenesis (increased 
production of melanin) are responsible for the hyperpigmentation in 
melasma. Kim et al. carried out a histological study to evaluate the 
vascular characteristics of melisma [17]. They found that vascular 
endothelial growth factor was increased in lesional skin in melasma 
signifying increased vascularization. This has clinical implications 
and indicates the need to devise treatment options to target the 
vascular component in melasma. In a prospective comparative split-
face randomized study carried out by Passeron et al., it was found that 
combination of TCC and pulsed dye laser (PDL) was more effective 
than TCC alone [18]. The combination treatment also prevented the 
relapses.
Kang et al. performed a transcriptional analysis in melasma skin 
samples and found that 279 genes were stimulated and 152 were 
found to be down regulated. Many melanin biosynthesis related 
genes as well as melanocyte markers such as TYR, MITF, SILV, and 
TYRP1 were found to be up regulated in melasma skin [19].
Several other genes involved in other biological pathways were 
found to be affected. These include Wnt pathway modulation genes, 
genes involved in prostaglandin synthesis and fatty acid metabolism 
[20].
Another interesting finding was the role of H19 gene in melasma 
pathogenesis as studied by Kim  et al. [20], H19 gene transcribes a 
noncoding ribonucleic acid (RNA) and is found to be down regulated 
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disease severity, pigmentation intensity, lesion area and colorimetry 
assessments [26].
In a randomized, split-face study, Monheit and Dreher compared 
the safety and efficacy of skin lightening cream (containing HQ 4% 
and four skin brightening actives) with a TCC (containing 4% HQ, 
0.05% tretinoin, and 0.01% fluocinolone acetonide) in 20 Caucasian 
female patients with melisma [26]. They found that after 4 weeks once 
daily treatment, the skin lightening cream SLC was comparable in 
both efficacy and safety to the well-established TCC treatment for 
melasma. One-third of patients experienced local side effects in the 
form of erythema, peeling of skin and dryness with both the creams.
In a randomized, controlled study Arellano et al. [27], compared 
the clinical efficacy and safety of two 6-month triple combination 
(containing HQ, fluocinolone acetonide and tretinoin) maintenance 
regimens in 242 Brazilian and Mexican patients with moderate-to-
severe melisma  [27]. Global severity score, melasma area severity 
index (MASI), and quality of life questionnaire were used to assess 
the efficacy of treatment. After eight weeks of daily TCC application, 
subjects were randomized to receive TCC in a twice weekly or 
tapering regimen (3/week [1st  month], 2/week [2nd  month], 1/week 
[4th  month]) for 6 months. They found that twice-weekly regimen 
showed better effectiveness on postponing relapse in patients with 
severe melasma. About 53% of patients were relapse-free after 6 
months.
Tretinoin: Tretinoin is widely used for the treatment of melasma 
as an over-the-counter lightening agent. Considering its efficacy, 
peeling with tretinoin may improve pigmentation in melasma. 
Faghihi et al. performed a randomized, double-blinded clinical trial 
to compare the efficacy of 1% tretinoin peel versus 70% GA peel in 
63 female patients with bilateral melisma [28]. It was found that the 
efficacy of 1% tretinoin peel was similar to 70% GA. Post  procedure 
discomfort as expressed by the patients was significantly lower with 
1% tretinoin.
Tretinoin can also be used as a peeling mask. Ghersetich  et 
al. evaluated the efficacy of 10% tretinoin peeling mask using 
standardized digital photos, mexameter measurement and MASI 
evaluation in 20 female patients with Fitzpatrick skin type II-VI [29]. 
They found moderate or marked improvement in all patients using 
these three parameters without any adverse events. At 10 weeks, the 
difference in the average MASI calculated at baseline and after 10 
weeks were 2.9.
Combination products: (Hydroquinone + Retinoids + Topical 
steroids), few other commonly used topical agents are Azelaic acid, 
Kojic acid, Ascorbic acid, Licorice extract, Soy.
Chemical peels: commonly used peels for melasma are AHA 
(Alpha Hydroxy Acid), SSA (Salicylic acid), Jessner solution 
(SSA+Lactic Acid+ Resorcinol+Ethanol), 10%-50% TCA 
(Trichloroacetic acid) peel.
In current practice and from experience chemical peels do not 
give satisfactory result, especially because of the skin type of our 
patients. We would not advise chemical peels due to chances of post 
inflammatory hyper &/or hypopigmentation that are very common 
in Skin type III-V.   
Laser and Light therapies: Various lasers that have been used for 
the treatment of melasma are:
•	 Green light: Flashlamp-pumped PDL (510 nm), frequency 
doubled Q switched neodymium: Yttrium aluminium 
garnet-532 nm (QS Nd: YAG)
•	 Red light: Q switched ruby (694 nm), Q switched alexandrite 
(755 nm)
•	 Near-infrared: QS Nd: YAG (1064 nm).
Fractional lasers have been used for the treatment of pigmented 
lesions, including melasma.
QS Nd: YAG is the most widely used laser for the treatment of 
melasma. The fluence used is less than 5 J/cm2, spot size 6 mm, and 
frequency of 10 Hz. The number of treatment sessions varies from 5 
to 10 at 1-week intervals.
Nowadays, technique called “laser toning” or “laser facial” has 
become increasingly popular for the treatment of melasma. This 
involves the use of a large spot size (6-8 mm), low fluence (1.6-3.5 J/
cm2) and multiple passes.
QS 1064 nm Nd: YAG laser performed every 1-2 weeks for 
several weeks [30], although good efficacy has been seen with this 
technique, side effects have also been reported. These include 
hypopigmentation, depigmentation, rebound hyperpigmentation, 
physical urticaria, acneiform eruption, petechiae, and herpes simplex 
reactivation. Combination of ablative and pigment selective lasers 
has also been tried in melasma. Ablative lasers remove the epidermis 
containing excess melanin; this is followed by the use of Q switched 
pigment selective laser that can target the dermal melanophages. 
Angsuwarangsee and Polnikorn studied the efficacy of combined 
ultrapulse CO2 laser and Q switched alexandrite laser (QSAL) alone 
in six patients with melasma. The site that received combination 
treatment showed significant response compared with the site that 
was treated with QSAL alone [30]. However, side effects in the 
form of contact dermatitis and hyperpigmentation were observed 
in few patients, especially in those with dark skin. Hence, the use of 
combination of lasers should only be used for refractory melasma.
On the horizon
4-n-Butylresorcinol is a derivative of resorcinol that inhibits 
tyrosinase and tyrosinase related protein enzymes in the melanin 
biosynthetic pathway [31], Studies have shown good efficacy and 
safety with 4-n-butylresorcinol in patients with melisma [32]. 
Huh  et al. [34], conducted a randomized controlled split-face trial 
in 23 patients with melasma to evaluate the efficacy and safety of 
liposome-encapsulated 4-n-butylresorcinol 0.1% cream. They found 
a statistically significant reduction (P < 0.043) in the melanin index 
on the treatment side [33].
Tranexamic Acid (TA) is Trans-4-(aminomethyl) cyclohexane 
carboxylic acid, a lysine analog that is in use as an antifibrinolytic 
agent for over 30 years. It inhibits UV-induced plasmin activity 
in keratinocytes by preventing the binding of plasminogen to 
the keratinocytes. This results in less free arachidonic acid and a 
diminished ability to produce prostaglandins, and this decreases 
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melanocyte tyrosinase activity. Zhang  et al. demonstrated that TA 
can interfere with the catalytic reaction of tyrosinase and inhibit 
melanogenesis [34]. In the treatment of melasma TA can be used 
orally, topically or by intradermal microinjection. As a hemostatic, 
TA is prescribed in a dose of 1000 mg 3 times daily, whereas in the 
treatment of melasma, it is used in a dose of 250 mg twice daily [35].
In a study conducted by Wu  et al., 74 Chinese patients with 
melasma were treated with TA 250 mg twice daily for 6 months. 
The effects of treatment were evaluated by two physicians and by the 
patients based on the reduction in melasma size and improvement 
of pigmentation. The results were excellent in 10.8%, good in 54%, 
fair in 31.1% and poor in 4.1%. Side effects seen were gastrointestinal 
discomfort and hypomenorrhea. Recurrence was seen in 9.5% 
patients [36]. 
TA can also be used topically. In a recent double-blind randomized 
prospective study by Kanechorn  et al., 5% TA incorporated in 
a liposome gel formulation was used in 23 Asian women with 
bilateral epidermal melasma. The treatment was given for 12 weeks 
and compared with the vehicle in a split-face trial [16,37]. 78.2% of 
patients showed a decrease in the melanin index. However, results 
were not significant as compared with vehicle. Another finding seen 
in this study was the erythema induced by topical TA.
In a study conducted by Lee  et al. [39], in 100 Korean women 
with melasma, TA was used intradermally (4 mg/ml) every week for 
12 weeks [38]. The treatment caused a significant decrease in MASI 
score (13.22 vs. 9.02 at week 8 and vs. 7.57 at week 12, P < 0.05 for 
both) with minimal side effects.
The advantage with TA is its good safety profile. Furthermore, it 
is temperature stable, UV insensitive and does not get oxidized easily. 
More studies are needed to evaluate its anti-melasma potential.
Similarly in our current practice the result of patients undergoing 
treatment with oral tranexamic acid 500mg once daily dosage is 
excellent. Improvement is expected and seen with an average of 1 to 
3months period.
Conclusion
Although not a disease in itself, vitiligo and melasma are the 
most common challenges dermatologists have to manage on daily 
basis. The treatment should not only focus on the superficial level 
but focus on various morbidities associated with it such as physical, 
social, cosmetic as well as psychological. The challenge is to make 
the patient as well as the society realize that; these are pigmentary 
disorder conditions rather than disease in itself. Patients may be 
reassured that the disorders are not life threatening or do not lead 
to physical disability, but it is well known that it can lead to drastic 
psychosocial consequences, especially in our part of the world .It is 
well understood in regions like Europe and America with skin type 1 
due to lack of colour contrast vitiligo is not much given concern but 
melasma and other hyperpigmentary disorders remain a common 
dermatological challenge.
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